Navigate this market better. Subscribe for FREE stock alerts and information.

Thursday, February 28, 2013

Valeant in active talks on merger, acquisition deals, (NYSE: VRX), (TSE: VRX.TO)

Valeant Pharmaceuticals International Inc is in active discussions on large and small acquisitions or merger deals, Chief Executive Michael Pearson said on Thursday. Valeant also sees greater value for shareholders from its December acquisition of U.S. rival Medicis than it was expecting earlier, Pearson said on a conference call with analysts to discuss fourth-quarter results.

Valeant Pharmaceuticals International, Inc., formerly Biovail Corporation, is a multinational, specialty pharmaceutical company that develops, manufactures and markets a range of pharmaceutical products. Shares of VRX remained unchanged at $66.74. In the past year, the shares have traded as low as $42.47 and as high as $67.98. On average, 1426920 shares of VRX exchange hands on a given day and today's volume is recorded at 0.

Valeant Pharmaceuticals International, Inc., formerly Biovail Corporation, is a multinational, specialty pharmaceutical company that develops, manufactures and markets a range of pharmaceutical products. Shares of VRX traded higher by 2.06% or $1.38/share to $68.25. In the past year, the shares have traded as low as $43.99 and as high as $68.86. On average, 430605 shares of VRX.TO exchange hands on a given day and today's volume is recorded at 0.



Source